Literature DB >> 28035197

Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.

Timothy M Block1, Tianlun Zhou1, Nikhil Anbarasan1, Robert Gish1.   

Abstract

Is a cure for chronic hepatitis B virus (HBV) infection possible? Hepatitis C virus infection is now routinely cured medically. There is a growing expectation that new drugs for the management of chronic HBV infection should provide substantial benefit over and above that of current chronic HBV medications, if not be curative. Although the definition of medically induced cure for chronic HBV infection varies, most include sustained off-drug absence of viremia and negativity for other virologic markers. There are currently more than 29 drugs in the pipeline being tested for the management of chronic HBV infection. This article discusses the potential drugs with respect to their possible contributions to achieving medically induced cure.

Entities:  

Keywords:  Hepatitis B virus; antivirals; endpoints; experimental therapy; therapy

Year:  2016        PMID： 28035197      PMCID： PMC5193088     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


  53 in total

Review 1.  American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  Robert P Perrillo; Robert Gish; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

Review 2.  Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

Authors:  Robert G Gish; Man-Fung Yuen; Henry Lik Yuen Chan; Bruce D Given; Ching-Lung Lai; Stephen A Locarnini; Johnson Y N Lau; Christine I Wooddell; Thomas Schluep; David L Lewis
Journal:  Antiviral Res       Date:  2015-06-27       Impact factor: 5.970

Review 3.  Targeting hepatitis B virus cccDNA using CRISPR/Cas9.

Authors:  Edward M Kennedy; Anand V R Kornepati; Bryan R Cullen
Journal:  Antiviral Res       Date:  2015-10-22       Impact factor: 5.970

4.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Authors:  Christopher Koh; Laetitia Canini; Harel Dahari; Xiongce Zhao; Susan L Uprichard; Vanessa Haynes-Williams; Mark A Winters; Gitanjali Subramanya; Stewart L Cooper; Peter Pinto; Erin F Wolff; Rachel Bishop; Ma Ai Thanda Han; Scott J Cotler; David E Kleiner; Onur Keskin; Ramazan Idilman; Cihan Yurdaydin; Jeffrey S Glenn; Theo Heller
Journal:  Lancet Infect Dis       Date:  2015-07-16       Impact factor: 25.071

Review 6.  Host-virus interactions in hepatitis B virus infection.

Authors:  Luca G Guidotti; Masanori Isogawa; Francis V Chisari
Journal:  Curr Opin Immunol       Date:  2015-07-15       Impact factor: 7.486

7.  Lamivudine for chronic delta hepatitis.

Authors:  D T Lau; E Doo; Y Park; D E Kleiner; P Schmid; M C Kuhns; J H Hoofnagle
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

Review 8.  Hepatitis delta: the rediscovery.

Authors:  Mario Rizzetto; Seyed Moayed Alavian
Journal:  Clin Liver Dis       Date:  2013-07-03       Impact factor: 6.126

9.  Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.

Authors:  Jang-June Park; David K Wong; Abdus S Wahed; William M Lee; Jordan J Feld; Norah Terrault; Mandana Khalili; Richard K Sterling; Kris V Kowdley; Natalie Bzowej; Daryl T Lau; W Ray Kim; Coleman Smith; Robert L Carithers; Keith W Torrey; James W Keith; Danielle L Levine; Daniel Traum; Suzanne Ho; Mary E Valiga; Geoffrey S Johnson; Edward Doo; Anna S F Lok; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2015-12-10       Impact factor: 22.682

Review 10.  Molecular viral oncology of hepatocellular carcinoma.

Authors:  Timothy M Block; Anand S Mehta; Claus J Fimmel; Robert Jordan
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867
View more
  1 in total

1.  Pathological changes of liver one year later in CHB patients with negative HBV DNA.

Authors:  Wu Shanshan; Du Xinfang; Yu Shuihong; Lai Kecong; Qi Jinjin; Chen Zhi; Chen Feng
Journal:  Infect Agent Cancer       Date:  2019-12-10       Impact factor: 2.965
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.